Beigene 311-308 / MAHOGANY

About this trial

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Patient Profile

Key Inclusion Criteria:

Histologically confirmed grade 1-3a FL or MZL
Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
Need for systemic therapy for FL or MZL
Measurable disease by computed tomography or magnetic resonance imaging
Adequate bone marrow, liver and renal function

Key Exclusion Criteria:

Transformation to aggressive lymphoma
Requiring ongoing need for corticosteroid treatment
Clinically significant cardiovascular disease
Prior malignancy within the past 2 years
Active fungal, bacterial, and/or viral infection that requires systemic therapy

Where’s this trial being run?

St James’s Hospital and University Hospital Waterford

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	Beigene 311-308 / MAHOGANY
Number:	24-30
Full Title:	A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Principal Investigator:
Type:	Industry Sponsored
Sponsor:	BeiGene
Recruitment Started:	Global: 10-Mar-2022 Ireland:

Global Recruitment Target:
Ireland Recruitment Target: